Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.99 SEK | -2.92% | -16.23% | -26.74% |
25/04 | Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
27/03 | Enzymatica AB Announces Composition of Nomination Committee | CI |
Sales 2024 * | 6.04M 66.04M 504M | Sales 2025 * | 11.85M 129M 988M | Capitalization | 48.71M 532M 4.06B |
---|---|---|---|---|---|
Net income 2024 * | -5M -54.64M -417M | Net income 2025 * | -1M -10.93M -83.43M | EV / Sales 2024 * | 8.59 x |
Net Debt 2024 * | 3.18M 34.79M 266M | Net cash position 2025 * | 2.05M 22.43M 171M | EV / Sales 2025 * | 3.94 x |
P/E ratio 2024 * |
-16.5
x | P/E ratio 2025 * |
-35.1
x | Employees | 18 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.79% |
1 day | -6.17% | ||
1 week | -16.23% | ||
Current month | -11.08% | ||
1 month | -11.89% | ||
3 months | -17.66% | ||
6 months | -22.83% | ||
Current year | -26.74% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Thomas Blom
FOU | Founder | 59 | 01/07/01 |
Claus Egstrand
CEO | Chief Executive Officer | 63 | 18/17/18 |
Director of Finance/CFO | 55 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bengt Baron
CHM | Chairman | 62 | 19/16/19 |
Director/Board Member | 56 | 15/16/15 | |
Director/Board Member | 57 | 01/21/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 2.99 | -2.92% | 221 083 |
26/24/26 | 3.08 | -4.94% | 173,251 |
25/24/25 | 3.24 | -8.22% | 96,511 |
24/24/24 | 3.53 | +2.62% | 12,555 |
23/24/23 | 3.44 | -0.29% | 23,983 |
Delayed Quote Nasdaq Stockholm, April 29, 2024 at 08:50 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.74% | 48.71M | |
+25.92% | 661B | |
+26.74% | 566B | |
-6.52% | 352B | |
+20.39% | 332B | |
+3.13% | 283B | |
+13.45% | 231B | |
+4.70% | 200B | |
-9.41% | 195B | |
-5.11% | 145B |
- Stock Market
- Equities
- ENZY Stock